L-dopa. II.
D000856:Anorexia Nervosa / Q000139:chemically induced; D005117:Cardiac Complexes, Premature / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D004357:Drug Synergism; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D001523:Mental Disorders / Q000139:chemically induced; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects; D009069:Movement Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy; D011736:Pyridoxine / Q000494:pharmacology; D013610:Tachycardia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D008996:Monoamine Oxidase Inhibitors; D004295:Dihydroxyphenylalanine; D011736:Pyridoxine